MedTrace Logo

Randomized Study Comparing Periodic Acceleration Versus Static Position in Cerebrovascular Stroke Patients

NCT02038998 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-02-15

No results posted yet for this study

Summary

Stroke is one of the leading causes of death and disability worldwide. More than 85% of strokes are due to blood vessel occlusion resulting in partial destruction of the brain parenchyma. Current protocols try to re-establish blood circulation as soon as possible through chemical and/or mechanical interventions but new strategies are needed.

Periodic acceleration (pGz) is a non-invasive method consisting in the application of a rocking movement to the patient that ultimately will induce the release of beneficial chemicals from the vascular endothelium (the cells lining the inside of the blood vessels). Application of pGz in an animal model of stroke resulted in a dramatic reduction of associated brain damage.

This trial will investigate whether stroke patients exposed to pGz experiment significantly higher recovery than patients that remained static during their treatment.

Conditions

  • Cerebrovascular Stroke

Interventions

DEVICE

Exer-Rest® TL

Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.

Sponsors & Collaborators

  • Hospital San Pedro de Logroño

    collaborator OTHER

  • Fundacion Rioja Salud

    lead OTHER

Principal Investigators

  • Francisco Julian-Villaverde, MD · Hospital San Pedro de Logroño

  • Alfredo Martinez, PhD · Fundacion Rioja Salud

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2022-05-31
Completion
2022-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02038998 on ClinicalTrials.gov